Progyny CFO Mark Livingston's Stock Sale Analysis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Fool
- Transaction Overview: On May 20, 2026, Progyny CFO Mark S. Livingston sold 8,275 shares of common stock in an open-market transaction valued at $211,000, reducing his direct holdings to 79,063 shares with a post-transaction value of $2.03 million.
- Holding Proportion Change: This sale represented 9.47% of Livingston's direct holdings, indicating a moderate reduction consistent with his previous trading cadence, suggesting no change in his selling intent.
- Market Performance Impact: The sale occurred at a price of $25.50 per share, close to the 52-week high of $28.75, and despite losing a major customer, Progyny's stock rose in Q2 2026 following strong full-year guidance.
- Future Growth Expectations: Progyny projects a revenue increase of 6% to 9% year-over-year for 2026, with potential growth rates of 10% to 13% when excluding sales from the large client, indicating increased income from other customers.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PGNY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PGNY
Wall Street analysts forecast PGNY stock price to rise
8 Analyst Rating
6 Buy
2 Hold
0 Sell
Strong Buy
Current: 26.890
Low
26.00
Averages
29.75
High
34.00
Current: 26.890
Low
26.00
Averages
29.75
High
34.00
About PGNY
Progyny, Inc. is a benefit management company. The Company specializes in fertility and family building benefits solutions in the United States. The Company’s clients include various employers across an array of industries. It has contracts to provide coverage to approximately 6.7 million employees and their partners (known as members). The Company provides its benefits through its proprietary Smart Cycle approach. Smart Cycles include the medical services required for a member’s full course of treatment, including all necessary diagnostic testing and access to the technology. In addition to its fertility benefits solution, the Company offers an integrated pharmacy benefits solution, Progyny Rx, which can be added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. It provides care management services, as well as medication administration training, pharmacy support services and continuing patient care advocate support.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Progyny CFO Mark Livingston's Stock Sale Analysis
- Transaction Overview: On May 20, 2026, Progyny CFO Mark S. Livingston sold 8,275 shares of common stock in an open-market transaction valued at $211,000, reducing his direct holdings to 79,063 shares with a post-transaction value of $2.03 million.
- Holding Proportion Change: This sale represented 9.47% of Livingston's direct holdings, indicating a moderate reduction consistent with his previous trading cadence, suggesting no change in his selling intent.
- Market Performance Impact: The sale occurred at a price of $25.50 per share, close to the 52-week high of $28.75, and despite losing a major customer, Progyny's stock rose in Q2 2026 following strong full-year guidance.
- Future Growth Expectations: Progyny projects a revenue increase of 6% to 9% year-over-year for 2026, with potential growth rates of 10% to 13% when excluding sales from the large client, indicating increased income from other customers.
See More
Progyny CFO Mark Livingston Sells Shares, Reduces Holdings
- Executive Sell-off: Progyny's CFO Mark Livingston sold 8,275 shares on May 20, 2026, for approximately $211,000, representing 9.47% of his holdings, reducing his direct ownership to 79,063 shares, indicating sensitivity to market conditions.
- Transaction Context: The shares were sold at $25.50 each, close to the 52-week high of $28.75, suggesting a strategic decision to realize gains during a price upswing, reflecting confidence in the company's future performance.
- Compliance with Trading Plan: The sale was executed under a pre-arranged Rule 10b5-1 trading plan established in August 2025, indicating that the transaction was non-discretionary and aimed at avoiding insider trading allegations, thereby enhancing investor trust in corporate governance.
- Positive Performance Outlook: Despite losing a major client, Progyny projects a revenue increase of 6% to 9% for 2026, and excluding the impact of this client, year-over-year growth could reach 10% to 13%, highlighting strong revenue potential from other customers.
See More
Progyny Director Kevin Gordon Sells Shares
- Share Sale Details: Kevin Gordon sold 5,500 shares on May 27, 2026, at a weighted average price of approximately $24.99 per share, totaling around $137,000, which represented 20.13% of his direct holdings, indicating a cautious approach towards the company's future.
- Ownership Structure: Post-sale, Gordon retains 15,027 shares indirectly through the Kevin Gordon Revocable Declaration of Trust, reflecting his continued confidence in Progyny despite the partial liquidation of his stake.
- Company Performance: Progyny reported a 1.4% year-over-year sales growth in Q1 2026, reaching $328 million, although revenue growth stalled due to the loss of a major client, yet gross profit increased by 10% to $83.1 million, showcasing efforts to enhance operational efficiency.
- Future Growth Outlook: Progyny expects total revenue to rise by 5.9% to 9.0% in 2026 and has approved a $200 million share repurchase program, indicating strong confidence in future market opportunities and a commitment to shareholder value.
See More
Progyny Insider Sells Shares Amid Positive Market Outlook
- Insider Share Sale: Progyny's Director Kevin K. Gordon sold 5,500 shares on May 27, 2026, for approximately $137,000, reducing his direct holdings to 6,792 shares, which indicates confidence in the company's future despite the sale.
- Ownership Proportion Analysis: This transaction represented 20.13% of Gordon's direct holdings, reflecting a significant decrease in his ownership over the past year, while he retains 15,027 indirect shares, demonstrating trust in the company's long-term prospects.
- Company Financial Performance: Progyny reported $328 million in revenue for Q1 2026, a 1.4% year-over-year increase, and despite a slowdown due to losing a major client, gross profit rose by 10% to $83.1 million, showcasing efforts to enhance operational efficiency.
- Future Growth Expectations: Progyny anticipates total revenue growth of 5.9% to 9.0% in 2026, and the board has approved a $200 million share repurchase program, indicating strong confidence in future performance and commitment to shareholders.
See More
Progyny Survey Reveals Importance of Human-Centric Healthcare
- Stress Management Challenges: The survey revealed that 71% of respondents felt their healthcare journey added stress to their daily lives, with primary sources being financial impacts, system complexity, and work-life balance issues, indicating a pressing need for improved healthcare services.
- Demand for Human Support: Over 70% of respondents expressed a desire for knowledgeable human support in every healthcare experience, highlighting the importance of interpersonal connections in an increasingly digital healthcare landscape, which may drive further development of Progyny's service model.
- Significant PCA Support Effects: 60% of respondents reported that interactions with Progyny Care Advocates (PCAs) helped reduce stress related to their care, with more than 75% stating that PCA support significantly alleviated their anxiety, demonstrating a strong market demand for personalized services.
- Importance of Emotional Support: The survey also found that 63% of respondents felt more educated and empowered in their healthcare journey, while 54% believed that PCAs helped them communicate better with providers, underscoring the critical role of emotional support in the healthcare process.
See More
Progyny Approves $200M Share Repurchase Program
- Share Repurchase Program: Progyny's board has approved a share repurchase program of up to $200 million, which will be funded through available cash balances, aimed at enhancing shareholder value and boosting market confidence.
- Stock Price Reaction: Following the announcement, Progyny's stock rose 1.6% in premarket trading to $25.28, indicating a positive market response to the company's repurchase initiative.
- Future Financial Outlook: Progyny anticipates revenue for 2026 to be between $1.365 billion and $1.405 billion, while adjusted EBITDA is expected to rise to between $232 million and $244 million, showcasing the company's growth potential.
- Strategic Market Implications: By implementing the share repurchase, Progyny not only strengthens its capital structure but may also attract more investor interest, thereby further solidifying its position in the competitive healthcare market.
See More
Progyny CFO Mark Livingston's Stock Sale Analysis
- Transaction Overview: On May 20, 2026, Progyny CFO Mark S. Livingston sold 8,275 shares of common stock in an open-market transaction valued at $211,000, reducing his direct holdings to 79,063 shares with a post-transaction value of $2.03 million.
- Holding Proportion Change: This sale represented 9.47% of Livingston's direct holdings, indicating a moderate reduction consistent with his previous trading cadence, suggesting no change in his selling intent.
- Market Performance Impact: The sale occurred at a price of $25.50 per share, close to the 52-week high of $28.75, and despite losing a major customer, Progyny's stock rose in Q2 2026 following strong full-year guidance.
- Future Growth Expectations: Progyny projects a revenue increase of 6% to 9% year-over-year for 2026, with potential growth rates of 10% to 13% when excluding sales from the large client, indicating increased income from other customers.
See More
Progyny CFO Mark Livingston Sells Shares, Reduces Holdings
- Executive Sell-off: Progyny's CFO Mark Livingston sold 8,275 shares on May 20, 2026, for approximately $211,000, representing 9.47% of his holdings, reducing his direct ownership to 79,063 shares, indicating sensitivity to market conditions.
- Transaction Context: The shares were sold at $25.50 each, close to the 52-week high of $28.75, suggesting a strategic decision to realize gains during a price upswing, reflecting confidence in the company's future performance.
- Compliance with Trading Plan: The sale was executed under a pre-arranged Rule 10b5-1 trading plan established in August 2025, indicating that the transaction was non-discretionary and aimed at avoiding insider trading allegations, thereby enhancing investor trust in corporate governance.
- Positive Performance Outlook: Despite losing a major client, Progyny projects a revenue increase of 6% to 9% for 2026, and excluding the impact of this client, year-over-year growth could reach 10% to 13%, highlighting strong revenue potential from other customers.
See More
Progyny Director Kevin Gordon Sells Shares
- Share Sale Details: Kevin Gordon sold 5,500 shares on May 27, 2026, at a weighted average price of approximately $24.99 per share, totaling around $137,000, which represented 20.13% of his direct holdings, indicating a cautious approach towards the company's future.
- Ownership Structure: Post-sale, Gordon retains 15,027 shares indirectly through the Kevin Gordon Revocable Declaration of Trust, reflecting his continued confidence in Progyny despite the partial liquidation of his stake.
- Company Performance: Progyny reported a 1.4% year-over-year sales growth in Q1 2026, reaching $328 million, although revenue growth stalled due to the loss of a major client, yet gross profit increased by 10% to $83.1 million, showcasing efforts to enhance operational efficiency.
- Future Growth Outlook: Progyny expects total revenue to rise by 5.9% to 9.0% in 2026 and has approved a $200 million share repurchase program, indicating strong confidence in future market opportunities and a commitment to shareholder value.
See More
Progyny Insider Sells Shares Amid Positive Market Outlook
- Insider Share Sale: Progyny's Director Kevin K. Gordon sold 5,500 shares on May 27, 2026, for approximately $137,000, reducing his direct holdings to 6,792 shares, which indicates confidence in the company's future despite the sale.
- Ownership Proportion Analysis: This transaction represented 20.13% of Gordon's direct holdings, reflecting a significant decrease in his ownership over the past year, while he retains 15,027 indirect shares, demonstrating trust in the company's long-term prospects.
- Company Financial Performance: Progyny reported $328 million in revenue for Q1 2026, a 1.4% year-over-year increase, and despite a slowdown due to losing a major client, gross profit rose by 10% to $83.1 million, showcasing efforts to enhance operational efficiency.
- Future Growth Expectations: Progyny anticipates total revenue growth of 5.9% to 9.0% in 2026, and the board has approved a $200 million share repurchase program, indicating strong confidence in future performance and commitment to shareholders.
See More
Progyny Survey Reveals Importance of Human-Centric Healthcare
- Stress Management Challenges: The survey revealed that 71% of respondents felt their healthcare journey added stress to their daily lives, with primary sources being financial impacts, system complexity, and work-life balance issues, indicating a pressing need for improved healthcare services.
- Demand for Human Support: Over 70% of respondents expressed a desire for knowledgeable human support in every healthcare experience, highlighting the importance of interpersonal connections in an increasingly digital healthcare landscape, which may drive further development of Progyny's service model.
- Significant PCA Support Effects: 60% of respondents reported that interactions with Progyny Care Advocates (PCAs) helped reduce stress related to their care, with more than 75% stating that PCA support significantly alleviated their anxiety, demonstrating a strong market demand for personalized services.
- Importance of Emotional Support: The survey also found that 63% of respondents felt more educated and empowered in their healthcare journey, while 54% believed that PCAs helped them communicate better with providers, underscoring the critical role of emotional support in the healthcare process.
See More
Progyny Approves $200M Share Repurchase Program
- Share Repurchase Program: Progyny's board has approved a share repurchase program of up to $200 million, which will be funded through available cash balances, aimed at enhancing shareholder value and boosting market confidence.
- Stock Price Reaction: Following the announcement, Progyny's stock rose 1.6% in premarket trading to $25.28, indicating a positive market response to the company's repurchase initiative.
- Future Financial Outlook: Progyny anticipates revenue for 2026 to be between $1.365 billion and $1.405 billion, while adjusted EBITDA is expected to rise to between $232 million and $244 million, showcasing the company's growth potential.
- Strategic Market Implications: By implementing the share repurchase, Progyny not only strengthens its capital structure but may also attract more investor interest, thereby further solidifying its position in the competitive healthcare market.
See More
